- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc stock price live, this page displays NASDAQ LXRX stock exchange data. View the LXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lexicon Pharmaceuticals Inc real time stock price chart below.
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 2.195.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 2.195.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
2.185
-0.015(-0.68%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.173
2.218
52 wk Range
1.000
2.680
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1732.218
52 wk Range
1.0002.680
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LXRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
3.770
Upside
+72.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Perk secures $300m credit facility to fund expansion
- Investing.com
- Perk secures $300m credit facility to fund expansion
- Investing.com
- Form 13D/A Lexicon Pharmaceuticals For: 8 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.770
(+72.54% Upside)
Lexicon Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue surged 1,523% to $21.1M vs. $1.3M prior year, driven by two $10M Novo Nordisk milestone payments for LX9851 licensing.
- Net loss improved 96% to $1.0M ($0.01/share) from $25.3M ($0.07/share) in Q1 2025; cash position strengthened to $199.7M, up $74.5M.
- Results exceeded forecasts with 115.75% revenue surprise ($21.1M vs. $9.78M expected); EPS beat at <$0.01 vs. ($0.04) forecast.
- Stock rose 3.75% in pre-market to $1.66; company reaffirmed FY2026 operating expense outlook and continues SONATA Phase III trial.
- R&D and SG&A expenses declined 16.3% and 20.7% respectively through strategic repositioning; analysts set $6 price target amid partnership optimism.
Last Updated: 2026-05-07, 10:32 a/m
Read Full TranscriptEarnings
Latest Release
May 07, 2026
EPS / Forecast
-- / -0.04
Revenue / Forecast
21.1M / 9.78M
Compare LXRX to Peers and Sector
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −37.5x | −1.4x | −0.4x | |
PEG Ratio | −0.43 | 0.38 | 0.00 | |
Price/Book | 4.8x | 1.6x | 2.6x | |
Price / LTM Sales | 14.0x | 23.1x | 3.1x | |
Upside (Analyst Target) | 40.9% | 276.2% | 51.8% | |
Fair Value Upside | Unlock | 6.7% | 7.5% | Unlock |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Lexicon (LXRX) Stock Price Today?
The Lexicon stock price today is 2.185 USD.
What Stock Exchange Does Lexicon Trade On?
Lexicon is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lexicon?
The stock symbol for Lexicon is "LXRX."
What Is the Lexicon Market Cap?
As of today, Lexicon market cap is 979.450M USD.
What Is Lexicon's Earnings Per Share (TTM)?
The Lexicon EPS (TTM) is -0.070.
When Is the Next Lexicon Earnings Date?
Lexicon will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is LXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Lexicon Stock Split?
Lexicon has split 1 times.
How Many Employees Does Lexicon Have?
Lexicon has 81 employees.
What is the current trading status of Lexicon (LXRX)?
As of Jul 16, 2026, Lexicon (LXRX) is trading at a price of 2.185 USD, with a previous close of 2.200 USD. The stock has fluctuated within a day range of 2.173 USD to 2.218 USD, while its 52-week range spans from 1.000 USD to 2.680 USD.
What Is Lexicon (LXRX) Price Target According to Analysts?
The average 12-month price target for Lexicon is 3.770 USD, with a high estimate of 6 USD and a low estimate of 1.75 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +72.54% Upside potential.
What Is the LXRX Premarket Price?
LXRX's last pre-market stock price is 2.220 USD. The pre-market share volume is 5,160.000, and the stock has decreased by 0.020, or 0.910%.
What Is the LXRX After Hours Price?
LXRX's last after hours stock price is 2.180 USD, the stock has decreased by -0.020, or -0.910%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.